News
BMY
57.33
+1.83%
1.03
Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Seeking Alpha · 1d ago
Want Decades of Passive Income? 3 Stocks to Buy Right Now
The Motley Fool · 2d ago
Buy/Sell: Wall Street’s top 10 stock calls this week
NASDAQ · 2d ago
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
Seeking Alpha · 2d ago
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Seeking Alpha · 3d ago
Bristol in license agreement with BioArctic for two Alzheimer's antibody programs
Seeking Alpha · 3d ago
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Benzinga · 3d ago
Regeneron reports positive results for two anti-coagulant drugs
Seeking Alpha · 3d ago
Impax Small Cap Fund Q3 2024 Commentary
Seeking Alpha · 4d ago
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
The Motley Fool · 4d ago
Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic
TipRanks · 4d ago
Bristol Myers added to Analyst Focus List at JPMorgan
TipRanks · 4d ago
Press Release: Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
Dow Jones · 4d ago
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
NASDAQ · 4d ago
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
The Motley Fool · 4d ago
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
The Motley Fool · 4d ago
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
Benzinga · 4d ago
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
Barchart · 4d ago
BMY Factor-Based Stock Analysis
NASDAQ · 4d ago
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.